European Society for Medical Oncology Asia Congress 2023
Format: 325 videos + 237 pdfs, size: 27.4 GB
Course Audience: oncologist
Overview:
- Start date: 01 Dec 2023
- End date: 03 Dec 2023
The ESMO Asia Congress 2023 welcomed Asian and international delegates in Singapore, from 1 to 3 December, to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level, and for the Asia-Pacific region.
The outstanding scientific programme covered the latest advances on the most prevalent cancer types in the region, offering high quality multidisciplinary educational sessions and special sessions, in collaboration with illustrious international and Asia-Pacific oncology associations.
As usual, there was a special focus on the Pan-Asian Guidelines Adaptation (PAGA) Lectures, conceived to share best practice standards of care for cancer patients, and providing a framework for the structured interaction of key opinion leaders in oncology from Asia and Europe.
The ESMO Asia Congress covers breakthroughs on the most prevalent cancer types in the region, and offers high quality multidisciplinary educational sessions, including the Pan Asian Adapted Guidelines Lectures, conceived to share best practice standards of care for patients with cancer.
Advances in systemic and loco Hepatic arterial infusion- Enhancing response in neoadjuvant or salvage (Video MP4 Format)
Advances in systemic and loco Hepatic arterial infusion- Enhancing response in neoadjuvant or salvage (PDF Format)Advances in systemic and loco Local and locoregional treatments- An update on current options (Video MP4 Format)Advances in systemic and loco Local and locoregional treatments- An update on current options (PDF Format)Advances in systemic and loco Q&A and discussion (Video MP4 Format)An eye on the future Bispecific antibodies Early activity signals in gastrointestinal tumours (Video MP4 Format)An eye on the future Bispecific antibodies Early activity signals in gastrointestinal tumours (PDF Format)An eye on the future Novel therapies for gastroesophageal cancer (Video MP4 Format)An eye on the future Novel therapies for gastroesophageal cancer (PDF Format)An eye on the future Q&A and discussion (Video MP4 Format)An eye on the future Targeted therapies in hepatobiliary cancers (Video MP4 Format)An eye on the future Targeted therapies in hepatobiliary cancers (PDF Format)Astellas Biomarker testing in gastric cancer- Solving practical issues and surmounting challenges (Video MP4 Format)Astellas Claudin as a therapeutic target in gastric cancer (Video MP4 Format)Astellas Conclusion (Video MP4 Format)Astellas Novel targeted therapy approaches in gastric cancer (Video MP4 Format)Astellas Panel discussion on the challenges of the management of gastric cancer (Video MP4 Format)Astellas Transformation of gastric cancer management in the past decade (from BSC to chemo to targeted + IO) (Video MP4 Format)Brain metastasis Q&A and discussion (Video MP4 Format)Brain metastasis Radiation for brain metastases- Upfront, at progression or nothing at all (Video MP4 Format)Brain metastasis Radiation for brain metastases- Upfront, at progression or nothing at all (PDF Format)Brain metastasis Standards and advances in the diagnosis and treatment of leptomeningeal disease (Video MP4 Format)Brain metastasis Standards and advances in the diagnosis and treatment of leptomeningeal disease (PDF Format)Challenges in melanoma treatment Adjuvant treatment in high-risk stage II melanoma- Do we still need SLNB (Video MP4 Format)Challenges in melanoma treatment Adjuvant treatment in high-risk stage II melanoma- Do we still need SLNB (PDF Format)Challenges in melanoma treatment Managing advanced acral and mucosal melanoma (Video MP4 Format)Challenges in melanoma treatment Managing advanced acral and mucosal melanoma (PDF Format)Challenges in melanoma treatment Q&A and discussion (Video MP4 Format)Collaborative session- Cellular therapies Cell-based therapies and the new EU Pharmaceutical Regulation proposal (Video MP4 Format)Collaborative session- Cellular therapies Challenges in the development and regulatory approval of cell-based therapies in Asia (Video MP4 Format)Collaborative session- Cellular therapies Challenges in the development and regulatory approval of cell-based therapies in Asia (PDF Format)Collaborative session- Cellular therapies Implementing cell-based therapies in reference centers and networks- Bottlenecks and opportunities (Video MP4 Format)Collaborative session- Cellular therapies Implementing cell-based therapies in reference centers and networks- Bottlenecks and opportunities (PDF Format)Collaborative session- Cellular therapies Q&A and discussion (Video MP4 Format)Collaborative session- Optimising drug Assessing the clinical value of new cancer therapeutics in real life settings- Tools and challenges (Video MP4 Format)Collaborative session- Optimising drug Assessing the clinical value of new cancer therapeutics in real life settings- Tools and challenges (PDF Format)Collaborative session- Optimising drug Early phase oncology drug development in Asia Pacific (Video MP4 Format)Collaborative session- Optimising drug Early phase oncology drug development in Asia Pacific (PDF Format)Collaborative session- Optimising drug Empowering networks and community hospitals for participation in cancer phase III trials (Video MP4 Format)Collaborative session- Optimising drug Empowering networks and community hospitals for participation in cancer phase III trials (PDF Format)Collaborative session- Optimising drug Introduction (Video MP4 Format)Collaborative session- Optimising drug Introduction (PDF Format)Collaborative session- Optimising drug Q&A and discussion (Video MP4 Format)Collaborative session- Optimising drug The optimal positioning and use of platform trial designs in drug development in oncology (Video MP4 Format)Collaborative session- Optimising drug The optimal positioning and use of platform trial designs in drug development in oncology (PDF Format)Collaborative session- The evolving screening Q&A and discussion (Video MP4 Format)Collaborative session- The evolving screening Strategies of molecular profiling of hepato biliary cancers- Perceived value and ongoing research (Video MP4 Format)Collaborative session- The evolving screening Strategies of molecular profiling of hepato biliary cancers- Perceived value and ongoing research (PDF Format)Collaborative session- The evolving screening Tackling survivorship issues in patients with hepato biliary cancers (Video MP4 Format)Collaborative session- The evolving screening Tackling survivorship issues in patients with hepato biliary cancers (PDF Format)Demystifying the treatment of uterine leiomyosarcoma A case of early stage LMS that will recur as a single lesion 7 months later (Video MP4 Format)Demystifying the treatment of uterine leiomyosarcoma A case of early stage LMS that will recur as a single lesion 7 months later (PDF Format)Demystifying the treatment of uterine leiomyosarcoma Defining the role of chemotherapy- When and which (Video MP4 Format)Demystifying the treatment of uterine leiomyosarcoma Defining the role of chemotherapy- When and which (PDF Format)Demystifying the treatment of uterine leiomyosarcoma Is there hope from molecular therapies (Video MP4 Format)Demystifying the treatment of uterine leiomyosarcoma Is there hope from molecular therapies (PDF Format)Demystifying the treatment of uterine leiomyosarcoma Q&A and discussion (Video MP4 Format)Demystifying the treatment of uterine leiomyosarcoma Should all patients receive radiotherapy (Video MP4 Format)Demystifying the treatment of uterine leiomyosarcoma Should all patients receive radiotherapy (PDF Format)Epidermal growth factor receptor Broader overview of screening in never smokers (Video MP4 Format)Epidermal growth factor receptor Broader overview of screening in never smokers (PDF Format)Epidermal growth factor receptor Chemotherapy and immunotherpay- Any role to play at all (Video MP4 Format)Epidermal growth factor receptor Chemotherapy and immunotherpay- Any role to play at all (PDF Format)Epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs)- Which one How long When (Video MP4 Format)Epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs)- Which one How long When (PDF Format)Epidermal growth factor receptor Integrating radiation in early stage EGFR (Video MP4 Format)Epidermal growth factor receptor Integrating radiation in early stage EGFR (PDF Format)Epidermal growth factor receptor Molecular testing minimal residual disease (MRD) (Video MP4 Format)Epidermal growth factor receptor Molecular testing minimal residual disease (MRD) (PDF Format)Epidermal growth factor receptor Q&A and discussion (Video MP4 Format)final_programme_asia2023 (PDF Format)First-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC) (Video MP4 Format)First-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC) (PDF Format)GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Breakthrough evolution in treatment landscape for solid tumors with ICIs (Video MP4 Format)GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors General Q&A and closing (Video MP4 Format)GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Key considerations in advanced_recurrent treatment of EC (Video MP4 Format)GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Novel checkpoint combinations for advanced NSCLC (Video MP4 Format)GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Perspective on single-agent PD-1 blockade in dMMR CRC_solid tumors (Video MP4 Format)Immunotherapy in nasopharyngeal carcinoma Biomarkers beyond PDL1 (Video MP4 Format)Immunotherapy in nasopharyngeal carcinoma Biomarkers beyond PDL1 (PDF Format)Immunotherapy in nasopharyngeal carcinoma Q&A and discussion (Video MP4 Format)Implication of lymphoma classification in 2023 Pathology aggressive B cell lymphomas (Video MP4 Format)Implication of lymphoma classification in 2023 Pathology aggressive B cell lymphomas (PDF Format)Implication of lymphoma classification in 2023 Q&A and discussion (Video MP4 Format)Implication of lymphoma classification in 2023 T cell lymphomas (Video MP4 Format)Implication of lymphoma classification in 2023 T cell lymphomas (PDF Format)Implication of lymphoma classification in 2023 Treatment of aggressive B cell lymphomas (Video MP4 Format)Implication of lymphoma classification in 2023 Treatment of aggressive B cell lymphomas (PDF Format)Implication of lymphoma classification in 2023 Treatment of T cell lymphomas (Video MP4 Format)Implication of lymphoma classification in 2023 Treatment of T cell lymphomas (PDF Format)Improving outcomes in high-risk genitourinary cancers Adjuvant and salvage radiation in prostate cancer (Video MP4 Format)Improving outcomes in high-risk genitourinary cancers Adjuvant and salvage radiation in prostate cancer (PDF Format)Improving outcomes in high-risk genitourinary cancers How to manage the conflicting adjuvant data in renal cell carcinoma (RCC) (Video MP4 Format)Improving outcomes in high-risk genitourinary cancers How to manage the conflicting adjuvant data in renal cell carcinoma (RCC) (PDF Format)Improving outcomes in high-risk genitourinary cancers Perioperative management of high-risk urothelial cancer (Video MP4 Format)Improving outcomes in high-risk genitourinary cancers Perioperative management of high-risk urothelial cancer (PDF Format)Improving outcomes in high-risk genitourinary cancers Q&A and discussion (Video MP4 Format)Improving outcomes in high-risk genitourinary cancers Updates on adjuvant therapy for testicular cancer (Video MP4 Format)Improving outcomes in high-risk genitourinary cancers Updates on adjuvant therapy for testicular cancer (PDF Format)Improving outcomes in high-risk genitourinary cancers Updates on penile cancer management (Video MP4 Format)Improving outcomes in high-risk genitourinary cancers Updates on penile cancer management (PDF Format)In collaboration with AACR Early detection of cancer Emerging multi-cancer detection technologies in liquid biopsies (Video MP4 Format)In collaboration with AACR Early detection of cancer Emerging multi-cancer detection technologies in liquid biopsies (PDF Format)In collaboration with AACR Early detection of cancer Genomic technologies for cancer risk prognostication and early detection (Video MP4 Format)In collaboration with AACR Early detection of cancer Genomic technologies for cancer risk prognostication and early detection (PDF Format)In collaboration with AACR Early detection of cancer Novel metabolic imaging approaches for early cancer detection (Video MP4 Format)In collaboration with AACR Early detection of cancer Novel metabolic imaging approaches for early cancer detection (PDF Format)In collaboration with AACR Early detection of cancer Novel study design and analysis for integrating multi-omics technologies for early detection of cancer (Video MP4 Format)In collaboration with AACR Early detection of cancer Novel study design and analysis for integrating multi-omics technologies for early detection of cancer (PDF Format)In collaboration with AACR Early detection of cancer Q&A and discussion (Video MP4 Format)In collaboration with AACR- Targeting the kinome Optimising combos of kinase inhibitors with other targeted agents (Video MP4 Format)In collaboration with AACR- Targeting the kinome Optimising combos of kinase inhibitors with other targeted agents (PDF Format)In collaboration with AACR- Targeting the kinome Optimising dose selection in phase I trials (Video MP4 Format)In collaboration with AACR- Targeting the kinome Optimising dose selection in phase I trials (PDF Format)In collaboration with AACR- Targeting the kinome Progress in preclinical development of targets and inhibitors (Video MP4 Format)In collaboration with AACR- Targeting the kinome Progress in preclinical development of targets and inhibitors (PDF Format)In collaboration with AACR- Targeting the kinome Q&A and discussion (Video MP4 Format)In collaboration with AACR- Targeting the kinome Selecting driver kinases in cell biology (Video MP4 Format)In collaboration with AACR- Targeting the kinome Selecting driver kinases in cell biology (PDF Format)ini oral session Genitourinary tumours Invited Discussant 210MO and 211MO (Video MP4 Format)ini oral session Genitourinary tumours Invited Discussant 210MO and 211MO (PDF Format)Latest updates in drug development New antibody drug conjugate (ADC) targets on the horizon (Video MP4 Format)Latest updates in drug development New antibody drug conjugate (ADC) targets on the horizon (PDF Format)Latest updates in drug development New therapies targeting RAS-RAF signalling in solid tumours (Video MP4 Format)Latest updates in drug development New therapies targeting RAS-RAF signalling in solid tumours (PDF Format)Latest updates in drug development Q&A and discussion (Video MP4 Format)Learnings from Europe- Policy options Conclusions- How to transfer these solutions to Asia (Video MP4 Format)Learnings from Europe- Policy options Conclusions- How to transfer these solutions to Asia (PDF Format)Learnings from Europe- Policy options Screening (Video MP4 Format)Learnings from Europe- Policy options Screening (PDF Format)Learnings from Europe- Policy options Setting the scene- EU’s Beating Cancer Plan & overview of cancer incidence in the Asia-Pacific region (Video MP4 Format)Learnings from Europe- Policy options Setting the scene- EU’s Beating Cancer Plan & overview of cancer incidence in the Asia-Pacific region (PDF Format)Learnings from Europe- Policy options Tobacco cessation lifestyle changes (Video MP4 Format)Learnings from Europe- Policy options Tobacco cessation lifestyle changes (PDF Format)Levelling up Reducing inequalities in outcomes Clinical Practice Guidelines (CPG) as tools to reduce inequities in the AP region (Video MP4 Format)Levelling up Reducing inequalities in outcomes Clinical Practice Guidelines (CPG) as tools to reduce inequities in the AP region (PDF Format)Levelling up Reducing inequalities in outcomes Inequities in access to standardsÿ of care in the AP region (Video MP4 Format)Levelling up Reducing inequalities in outcomes Inequities in access to standardsÿ of care in the AP region (PDF Format)Levelling up Reducing inequalities in outcomes Measuring inequities in a single country (Video MP4 Format)Levelling up Reducing inequalities in outcomes Measuring inequities in a single country (PDF Format)Levelling up Reducing inequalities in outcomes Setting the scene- Overview of key inequalities in theÿAsia-Pacific (AP) region and worldwide (PDF Format)Levelling up Reducing inequalities in outcomes The strategies of ERN to reduce inequities in EU (example of Genturis or Euracan) (Video MP4 Format)Levelling up Reducing inequalities in outcomes The strategies of ERN to reduce inequities in EU (example of Genturis or Euracan) (PDF Format)Leveraging the molecular biology Enhancing immunotherapy responsiveness in squamous versus adenocarcinoma based on molecular biology (focus on primarily esophageal cancer) (Video MP4 Format)Leveraging the molecular biology Enhancing immunotherapy responsiveness in squamous versus adenocarcinoma based on molecular biology (focus on primarily esophageal cancer) (PDF Format)Leveraging the molecular biology Immunotherapy in microsatellite stable (MSS) luminal gastrointestinal cancers (Video MP4 Format)Leveraging the molecular biology Immunotherapy in microsatellite stable (MSS) luminal gastrointestinal cancers (PDF Format)Leveraging the molecular biology Leveraging the molecular biology of hepatocellular carcinoma (HCC) in optimising response to immunotherapy (Video MP4 Format)Leveraging the molecular biology Leveraging the molecular biology of hepatocellular carcinoma (HCC) in optimising response to immunotherapy (PDF Format)Leveraging the molecular biology Q&A and discussion (Video MP4 Format)Management of central nervous system Emerging systemic therapy options for CNS disease in HER2+ metastatic breast cancer (Video MP4 Format)Management of central nervous system Emerging systemic therapy options for CNS disease in HER2+ metastatic breast cancer (PDF Format)Management of central nervous system Imaging modalities to diagnose and assess CNS disease in metastatic breast cancer- Which to choose and when (Video MP4 Format)Management of central nervous system Imaging modalities to diagnose and assess CNS disease in metastatic breast cancer- Which to choose and when (PDF Format)Management of central nervous system Presentation of case condition (Video MP4 Format)Management of central nervous system Presentation of case condition (PDF Format)Management of central nervous system Q&A and discussion (Video MP4 Format)Management of central nervous system State of the art locoregional therapy for CNS metastases in metastatic HER2+ breast cancer (Video MP4 Format)Management of central nervous system State of the art locoregional therapy for CNS metastases in metastatic HER2+ breast cancer (PDF Format)Mini oral session 1 Gastrointestinal tumours Invited Discussant 132MO and 133MO (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Invited Discussant 132MO and 133MO (PDF Format)Mini oral session 1 Gastrointestinal tumours Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) (PDF Format)Mini oral session 1 Gastrointestinal tumours Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem cis) compared with gem cis (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem cis) compared with gem cis (PDF Format)Mini oral session 1 Gastrointestinal tumours Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H) (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H) (PDF Format)Mini oral session 1 Gastrointestinal tumours Q&A and discussion 1 (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Q&A and discussion 2 (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Q&A and discussion 3 (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated (PDF Format)Mini oral session 1 Gastrointestinal tumours Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS (PDF Format)Mini oral session 1 Gastrointestinal tumours Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (Video MP4 Format)Mini oral session 1 Gastrointestinal tumours Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (PDF Format)Mini oral session 1 Thoracic cancer Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic (Video MP4 Format)Mini oral session 1 Thoracic cancer Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic (PDF Format)Mini oral session 1 Thoracic cancer Dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous (Video MP4 Format)Mini oral session 1 Thoracic cancer Dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous (PDF Format)Mini oral session 1 Thoracic cancer Invited Discussant 508MO, 509MO and 510MO (Video MP4 Format)Mini oral session 1 Thoracic cancer Invited Discussant 508MO, 509MO and 510MO (PDF Format)Mini oral session 1 Thoracic cancer Invited Discussant LBA13 and 511MO (Video MP4 Format)Mini oral session 1 Thoracic cancer Invited Discussant LBA13 and 511MO (PDF Format)Mini oral session 1 Thoracic cancer Q&A and discussion (Video MP4 Format)Mini oral session 1 Thoracic cancer Tarlatamab for patients (pts) with previously treated small cell lung cance (Video MP4 Format)Mini oral session 1 Thoracic cancer Tarlatamab for patients (pts) with previously treated small cell lung cance (PDF Format)Mini oral session 1 Thoracic cancer Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (Video MP4 Format)Mini oral session 1 Thoracic cancer Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (PDF Format)Mini oral session 2 Gastrointestinal tumours Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients (PDF Format)Mini oral session 2 Gastrointestinal tumours Invited Discussant 134MO, 135MO and 136MO (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Invited Discussant 134MO, 135MO and 136MO (PDF Format)Mini oral session 2 Gastrointestinal tumours Invited Discussant 138MO and 139MO (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Invited Discussant 138MO and 139MO (PDF Format)Mini oral session 2 Gastrointestinal tumours Q&A and discussion 1 (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Q&A and discussion 2 (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (PDF Format)Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab (PDF Format)Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab (Video MP4 Format)Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab (PDF Format)Mini oral session 2 Thoracic cancer Acquired mechanisms of resistance to first-line (1L) osimertinib (Video MP4 Format)Mini oral session 2 Thoracic cancer Acquired mechanisms of resistance to first-line (1L) osimertinib (PDF Format)Mini oral session 2 Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian (Video MP4 Format)Mini oral session 2 Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian (PDF Format)Mini oral session 2 Thoracic cancer Efficacy and safety of MCLA-129, an anti-EGFRc-MET bispecific antibody (Video MP4 Format)Mini oral session 2 Thoracic cancer Efficacy and safety of MCLA-129, an anti-EGFRc-MET bispecific antibody (PDF Format)Mini oral session 2 Thoracic cancer Final overall survival (OS) results of befotertinib in patients with pretreated EGFR (Video MP4 Format)Mini oral session 2 Thoracic cancer Final overall survival (OS) results of befotertinib in patients with pretreated EGFR (PDF Format)Mini oral session 2 Thoracic cancer FLAURA2 Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC (Video MP4 Format)Mini oral session 2 Thoracic cancer FLAURA2 Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC (PDF Format)Mini oral session 2 Thoracic cancer Invited Discussant 490MO and 518MO (Video MP4 Format)Mini oral session 2 Thoracic cancer Invited Discussant 490MO and 518MO (PDF Format)Mini oral session 2 Thoracic cancer Invited Discussant 512MO, 513MO and 514MO (Video MP4 Format)Mini oral session 2 Thoracic cancer Invited Discussant 512MO, 513MO and 514MO (PDF Format)Mini oral session 2 Thoracic cancer Invited Discussant LBA9, 515MO and 516MO (Video MP4 Format)Mini oral session 2 Thoracic cancer Invited Discussant LBA9, 515MO and 516MO (PDF Format)Mini oral session 2 Thoracic cancer Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Video MP4 Format)Mini oral session 2 Thoracic cancer Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (PDF Format)Mini oral session 2 Thoracic cancer Q&A and discussion 1 (Video MP4 Format)Mini oral session 2 Thoracic cancer Q&A and discussion 2 (Video MP4 Format)Mini oral session 2 Thoracic cancer Q&A and discussion 3 (Video MP4 Format)Mini oral session 2 Thoracic cancerPatient-reported outcomes of first-line selpercatinib versus chemotherapy (Video MP4 Format)Mini oral session 2 Thoracic cancerPatient-reported outcomes of first-line selpercatinib versus chemotherapy (PDF Format)Mini oral session Breast cancer A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic (Video MP4 Format)Mini oral session Breast cancer A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic (PDF Format)Mini oral session Breast cancer Analytical and clinical validation of a ctDNA-based assay for multi-cancer detection (Video MP4 Format)Mini oral session Breast cancer Analytical and clinical validation of a ctDNA-based assay for multi-cancer detection (PDF Format)Mini oral session Breast cancer First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) (Video MP4 Format)Mini oral session Breast cancer First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) (PDF Format)Mini oral session Breast cancer Image biomarker discovery from DCE-MRI for identifying responders (Video MP4 Format)Mini oral session Breast cancer Image biomarker discovery from DCE-MRI for identifying responders (PDF Format)Mini oral session Breast cancer Invited Discussant LBA3, LBA6 and 57MO (PDF Format)Mini oral session Breast cancer Invited Discussant one LBA2, 1MO and 56MO (Video MP4 Format)Mini oral session Breast cancer Invited Discussant one LBA2, 1MO and 56MO (PDF Format)Mini oral session Breast cancer Landscape of ESR1 mutations in advanced breast cancer using circulating tumor DNA (Video MP4 Format)Mini oral session Breast cancer Landscape of ESR1 mutations in advanced breast cancer using circulating tumor DNA (PDF Format)Mini oral session Breast cancer Multimodal data fusion enhanced precision neoadjuvant chemotherapy in breast cancer (Video MP4 Format)Mini oral session Breast cancer Multimodal data fusion enhanced precision neoadjuvant chemotherapy in breast cancer (PDF Format)Mini oral session Breast cancer Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy (Video MP4 Format)Mini oral session Breast cancer Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy (PDF Format)Mini oral session Breast cancer Q&A and discussion 1 (Video MP4 Format)Mini oral session Breast cancer Q&A and discussion 2 (Video MP4 Format)Mini oral session Breast cancer Q&A and discussion 3 (Video MP4 Format)Mini oral session Genitourinary tumours 1 (Video MP4 Format)Mini oral session Genitourinary tumours 2 (Video MP4 Format)Mini oral session Genitourinary tumours 3 (Video MP4 Format)Mini oral session Genitourinary tumours Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume (Video MP4 Format)Mini oral session Genitourinary tumours Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume (PDF Format)Mini oral session Genitourinary tumours Enzalutamide versus abiraterone plus prednisolone for Japanese non-metastatic (Video MP4 Format)Mini oral session Genitourinary tumours Enzalutamide versus abiraterone plus prednisolone for Japanese non-metastatic (PDF Format)Mini oral session Genitourinary tumours EV-302KEYNOTE-A39- Open-label, randomized phase III study of enfortumab (Video MP4 Format)Mini oral session Genitourinary tumours EV-302KEYNOTE-A39- Open-label, randomized phase III study of enfortumab (PDF Format)Mini oral session Genitourinary tumours Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC) (Video MP4 Format)Mini oral session Genitourinary tumours Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC) (PDF Format)Mini oral session Genitourinary tumours Invited Discussant 258MO and 260MO (Video MP4 Format)Mini oral session Genitourinary tumours Invited Discussant 258MO and 260MO (PDF Format)Mini oral session Genitourinary tumours Low dose nivolumab with TKI in mRCC- Dosing strategies, de-escalation and survival among self-paying patients in India (Video MP4 Format)Mini oral session Genitourinary tumours Low dose nivolumab with TKI in mRCC- Dosing strategies, de-escalation and survival among self-paying patients in India (PDF Format)Mini oral session Genitourinary tumours Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) (Video MP4 Format)Mini oral session Genitourinary tumours Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) (PDF Format)Mini oral session Haematological malignancies Genetic landscape and prognostic value of IRF4 alterations in diffuse large B cell lymphoma patients (Video MP4 Format)Mini oral session Haematological malignancies Genetic landscape and prognostic value of IRF4 alterations in diffuse large B cell lymphoma patients (PDF Format)Mini oral session Haematological malignancies HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis (Video MP4 Format)Mini oral session Haematological malignancies HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis (PDF Format)Mini oral session Haematological malignancies Invited Discussant 328MO, 329MO and 330MO (Video MP4 Format)Mini oral session Haematological malignancies Invited Discussant 328MO, 329MO and 330MO (PDF Format)Mini oral session Haematological malignancies Invited Discussant 331MO and 332MO (Video MP4 Format)Mini oral session Haematological malignancies Invited Discussant 331MO and 332MO (PDF Format)Mini oral session Haematological malignancies Invited Discussant 333MO and 334MO (Video MP4 Format)Mini oral session Haematological malignancies Invited Discussant 333MO and 334MO (PDF Format)Mini oral session Haematological malignancies Invited Discussant 335MO and 336MO (Video MP4 Format)Mini oral session Haematological malignancies Invited Discussant 335MO and 336MO (PDF Format)Mini oral session Haematological malignancies Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies (Video MP4 Format)Mini oral session Haematological malignancies Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies (PDF Format)Mini oral session Haematological malignancies Q&A and discussion 1 (Video MP4 Format)Mini oral session Haematological malignancies Q&A and discussion 2 (Video MP4 Format)Mini oral session Haematological malignancies Q&A and discussion 3 (Video MP4 Format)Mini oral session Haematological malignancies Real-world outcomes of diffuse large B cell lymphoma treated (Video MP4 Format)Mini oral session Haematological malignancies Real-world outcomes of diffuse large B cell lymphoma treated (PDF Format)Mini oral session Haematological malignancies Treatment patterns in patients with mantle cell lymphoma (Video MP4 Format)Mini oral session Haematological malignancies Treatment patterns in patients with mantle cell lymphoma (PDF Format)Mini oral session Head and neck cancer Characterizing the role of NSD family of histone methyltransferases in the head and neck squamous cell carcinoma tumor immune microenvironment (Video MP4 Format)Mini oral session Head and neck cancer Characterizing the role of NSD family of histone methyltransferases in the head and neck squamous cell carcinoma tumor immune microenvironment (PDF Format)Mini oral session Head and neck cancer Comparison of long-term quality of life between survivors of adolescent and adult nasopharyngeal carcinoma (Video MP4 Format)Mini oral session Head and neck cancer Comparison of long-term quality of life between survivors of adolescent and adult nasopharyngeal carcinoma (PDF Format)Mini oral session Head and neck cancer Invited Discussant 357MO and 358MO (Video MP4 Format)Mini oral session Head and neck cancer Invited Discussant 357MO and 358MO (PDF Format)Mini oral session Head and neck cancer Invited Discussant 359MO, 360MO and 361MO (Video MP4 Format)Mini oral session Head and neck cancer Invited Discussant 359MO, 360MO and 361MO (PDF Format)Mini oral session Head and neck cancer Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment (Video MP4 Format)Mini oral session Head and neck cancer Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment (PDF Format)Mini oral session Head and neck cancer Phase I dose-escalation study of nab-paclitaxel combined with cisplatin (Video MP4 Format)Mini oral session Head and neck cancer Phase I dose-escalation study of nab-paclitaxel combined with cisplatin (PDF Format)Mini oral session Head and neck cancer Q&A and discussion 1 (Video MP4 Format)Mini oral session Head and neck cancer Q&A and discussion 2 (Video MP4 Format)Mini oral session Head and neck cancer Quality-adjusted life-year and life-year estimates for patients (Video MP4 Format)Mini oral session Head and neck cancer Quality-adjusted life-year and life-year estimates for patients (PDF Format)Mini oral session Supportive and palliative care Barriers and facilitators of home-based exercise intervention (Video MP4 Format)Mini oral session Supportive and palliative care Barriers and facilitators of home-based exercise intervention (PDF Format)Mini oral session Supportive and palliative care Cost-effective evaluation of homemade diet recipe in head and neck cancer (PDF Format)Mini oral session Supportive and palliative care Impact of Nada yoga music therapy on anxiety and quality of life in ovarian cancer patients (Video MP4 Format)Mini oral session Supportive and palliative care Impact of Nada yoga music therapy on anxiety and quality of life in ovarian cancer patients (PDF Format)Mini oral session Supportive and palliative care Increased eosinophil is a universal biomarker for immune-related (Video MP4 Format)Mini oral session Supportive and palliative care Increased eosinophil is a universal biomarker for immune-related (PDF Format)Mini oral session Supportive and palliative care Invited Discussant 394MO and 395MO (Video MP4 Format)Mini oral session Supportive and palliative care Invited Discussant 394MO and 395MO (PDF Format)Mini oral session Supportive and palliative care Invited Discussant 433MO and 434MO (Video MP4 Format)Mini oral session Supportive and palliative care Invited Discussant 433MO and 434MO (PDF Format)Mini oral session Supportive and palliative care Prognostic models for survival predictions in advanced cancer patients- A systematic review and meta-analysis (Video MP4 Format)Mini oral session Supportive and palliative care Prognostic models for survival predictions in advanced cancer patients- A systematic review and meta-analysis (PDF Format)Mini oral session Supportive and palliative care Q&A and discussion 1 (Video MP4 Format)Mini oral session Supportive and palliative care Q&A and discussion 2 (Video MP4 Format)Mini oral session Supportive and palliative care Q&A and discussion 3 (Video MP4 Format)Mini oral session Supportive and palliative care Structure of QOLLTI-F in Chinese-speaking carers of palliative care patients (Video MP4 Format)Mini oral session Supportive and palliative care Structure of QOLLTI-F in Chinese-speaking carers of palliative care patients (PDF Format)Mini oral session Supportive and palliative care Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy (Video MP4 Format)Mini oral session Supportive and palliative care Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy (PDF Format)Mixed Proffered paper and Mini oral session A first-in-human, open-label, dose-escalation study of ERK12 (Video MP4 Format)Mixed Proffered paper and Mini oral session A first-in-human, open-label, dose-escalation study of ERK12 (PDF Format)Mixed Proffered paper and Mini oral session Efficacy and safety findings from MANTRA (Video MP4 Format)Mixed Proffered paper and Mini oral session Efficacy and safety findings from MANTRA (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Determining the maximum tolerated dose of paclitaxel combined (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Determining the maximum tolerated dose of paclitaxel combined (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy and safety of topical sintilimab administration (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy and safety of topical sintilimab administration (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy of low dose nivolumab in recurrent metastatic cervical cancer (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy of low dose nivolumab in recurrent metastatic cervical cancer (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts) (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts) (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers InnovaTV 301ENGOT-cx12GOG-3057 (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers InnovaTV 301ENGOT-cx12GOG-3057 (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 285O, 286MO and 287MO (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 285O, 286MO and 287MO (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 288MO, 289MO and 290MO (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 288MO, 289MO and 290MO (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant LBA8 and 291MO (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant LBA8 and 291MO (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Preliminary efficacy of pembrolizumab plus lenvatinib (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Preliminary efficacy of pembrolizumab plus lenvatinib (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Prevalence of homologous recombination deficiency in ovarian, primary peritoneal (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Prevalence of homologous recombination deficiency in ovarian, primary peritoneal (PDF Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Q&A and discussion 1 (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Q&A and discussion 2 (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Q&A and discussion 3 (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Real-world experience with maintenance PARP inhibitor plus minus bevacizumab (Video MP4 Format)Mixed Proffered paper and Mini oral session Gynaecological cancers Real-world experience with maintenance PARP inhibitor plus minus bevacizumab (PDF Format)Mixed Proffered paper and Mini oral session Invited Discussant 402O (Video MP4 Format)Mixed Proffered paper and Mini oral session Invited Discussant 402O (PDF Format)Mixed Proffered paper and Mini oral session Invited Discussant 404MO and 405MO (Video MP4 Format)Mixed Proffered paper and Mini oral session Invited Discussant 404MO and 405MO (PDF Format)Mixed Proffered paper and Mini oral session Invited Discussant 74MO, 75MO, 76MO and 77MO (Video MP4 Format)Mixed Proffered paper and Mini oral session Invited Discussant 74MO, 75MO, 76MO and 77MO (PDF Format)Mixed Proffered paper and Mini oral session Pan-cancer analysis of 4-1BB transcriptome expression (Video MP4 Format)Mixed Proffered paper and Mini oral session Pan-cancer analysis of 4-1BB transcriptome expression (PDF Format)Mixed Proffered paper and Mini oral session Phase I trial of the DLL3CD3 IgG-like T cell (Video MP4 Format)Mixed Proffered paper and Mini oral session Phase I trial of the DLL3CD3 IgG-like T cell (PDF Format)Mixed Proffered paper and Mini oral session Q&A and discussion 1 (Video MP4 Format)Mixed Proffered paper and Mini oral session Q&A and discussion 2 (Video MP4 Format)Mixed Proffered paper and Mini oral session Q&A and discussion 3 (Video MP4 Format)Mixed Proffered paper and Mini oral session Tertiary lymphoid structures localization and maturation heterogeneities (Video MP4 Format)Mixed Proffered paper and Mini oral session Tertiary lymphoid structures localization and maturation heterogeneities (PDF Format)Mixed Proffered paper and Mini oral session Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) (Video MP4 Format)Mixed Proffered paper and Mini oral session Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) (PDF Format)New treatment options for sarcomas Q&A and discussion (Video MP4 Format)New treatment options for sarcomas What is new in treatments for liposarcoma (Video MP4 Format)New treatment options for sarcomas What is new in treatments for liposarcoma (PDF Format)New treatment options for sarcomas What is new in treatments for tenosynovial giant cell tumor (TGCT) (Video MP4 Format)New treatment options for sarcomas What is new in treatments for tenosynovial giant cell tumor (TGCT) (PDF Format)New treatment options for sarcomas What is new in treatments for ultra-rare sarcomas (Video MP4 Format)New treatment options for sarcomas What is new in treatments for ultra-rare sarcomas (PDF Format)Non-small cell lung cancer Mechanisms of resistance to immunotherapy (Video MP4 Format)Non-small cell lung cancer Mechanisms of resistance to immunotherapy (PDF Format)Non-small cell lung cancer Q&A and discussion (Video MP4 Format)Non-small cell lung cancer Role of local treatment (Video MP4 Format)Non-small cell lung cancer Role of local treatment (PDF Format)Novel approaches and challenges for treatment of head and neck cancer Boron neutron capture therapy (BNCT) as an emerging tool to treat head and neck cancer (Video MP4 Format)Novel approaches and challenges for treatment of head and neck cancer Boron neutron capture therapy (BNCT) as an emerging tool to treat head and neck cancer (PDF Format)Novel approaches and challenges for treatment of head and neck cancer Challenges to overcoming radio-resistance in head and neck cancer (Video MP4 Format)Novel approaches and challenges for treatment of head and neck cancer Challenges to overcoming radio-resistance in head and neck cancer (PDF Format)Novel approaches and challenges for treatment of head and neck cancer Novel immunotherapy approaches for head and neck cancer (Video MP4 Format)Novel approaches and challenges for treatment of head and neck cancer Novel immunotherapy approaches for head and neck cancer (PDF Format)Novel approaches and challenges for treatment of head and neck cancer Q&A and discussion (Video MP4 Format)Novel approaches and challenges for treatment of head and neck cancer Tumour biology and clinical outcomes in head and neck cancer- Does gender matter (Video MP4 Format)Novel approaches and challenges for treatment of head and neck cancer Tumour biology and clinical outcomes in head and neck cancer- Does gender matter (PDF Format)Novel therapies shaping the treatment landscape of gynecologic malignancies ADCs in gynaecological malignancies (Video MP4 Format)Novel therapies shaping the treatment landscape of gynecologic malignancies ADCs in gynaecological malignancies (PDF Format)Novel therapies shaping the treatment landscape of gynecologic malignancies Immunotherapy in gynecologic malignancies- Current role and future prospects (Video MP4 Format)Novel therapies shaping the treatment landscape of gynecologic malignancies Immunotherapy in gynecologic malignancies- Current role and future prospects (PDF Format)Novel therapies shaping the treatment landscape of gynecologic malignancies Managing the toxicities of novel compounds (Video MP4 Format)Novel therapies shaping the treatment landscape of gynecologic malignancies Managing the toxicities of novel compounds (PDF Format)Novel therapies shaping the treatment landscape of gynecologic malignancies Predictive biomarkers of response to immunotherapy and ADC in gynecological cancer (Video MP4 Format)Novel therapies shaping the treatment landscape of gynecologic malignancies Predictive biomarkers of response to immunotherapy and ADC in gynecological cancer (PDF Format)Novel therapies shaping the treatment landscape of gynecologic malignancies Q&A and discussion (Video MP4 Format)Oncogene-driven non-small cell lung cancer HER2 mutation (Video MP4 Format)Oncogene-driven non-small cell lung cancer HER2 mutation (PDF Format)Oncogene-driven non-small cell lung cancer KRAS (Video MP4 Format)Oncogene-driven non-small cell lung cancer KRAS (PDF Format)Oncogene-driven non-small cell lung cancer New fusions RET, NTRK, ROS1 (Video MP4 Format)Oncogene-driven non-small cell lung cancer New fusions RET, NTRK, ROS1 (PDF Format)Oncogene-driven non-small cell lung cancer Q&A and discussion (Video MP4 Format)Opening session and Keynote lecture Scientific Co-Chairs- Programme and key highlights of the meeting (Video MP4 Format)Opening session and Keynote lecture Token of Appreciation Endorsing society representatives (Video MP4 Format)Opening session and Keynote lecture Welcome address by the ESMO President, Prof. Andr‚s Cervantes (Video MP4 Format)Opening session and Keynote lecture Welcome address by the ESMO President, Prof. Andr‚s Cervantes (PDF Format)Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Early breast cancer (Video MP4 Format)Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Early breast cancer (PDF Format)Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Gastric cancer (Video MP4 Format)Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Gastric cancer (PDF Format)Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Early breast cancer (Video MP4 Format)Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Early breast cancer (PDF Format)Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Gastric cancer (Video MP4 Format)Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Gastric cancer (PDF Format)Practicing oncology across the globe Q&A and discussion 1 (Video MP4 Format)Practicing oncology across the globe Q&A and discussion 2 (Video MP4 Format)Presidential Symposium Asian subgroup analysis of the THOR phase III study- Erdafitinib versus chemotherapy (Video MP4 Format)Presidential Symposium Asian subgroup analysis of the THOR phase III study- Erdafitinib versus chemotherapy (PDF Format)Presidential Symposium Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (Video MP4 Format)Presidential Symposium Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (PDF Format)Presidential Symposium EXCLAIM-2 Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy (Video MP4 Format)Presidential Symposium EXCLAIM-2 Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy (PDF Format)Presidential Symposium Invited Discussant 208O (Video MP4 Format)Presidential Symposium Invited Discussant 208O (PDF Format)Presidential Symposium Invited Discussant 507O (Video MP4 Format)Presidential Symposium Invited Discussant 507O (PDF Format)Presidential Symposium Invited Discussant LBA1 (Video MP4 Format)Presidential Symposium Invited Discussant LBA1 (PDF Format)Presidential Symposium Q&A and discussion 1 (Video MP4 Format)Presidential Symposium Q&A and discussion 2 (Video MP4 Format)Presidential Symposium Q&A and discussion 3 (Video MP4 Format)Proffered Paper session Breast cancer Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (Video MP4 Format)Proffered Paper session Breast cancer Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (PDF Format)Proffered Paper session Breast cancer Invited Discussant one LBA4 and 54O (Video MP4 Format)Proffered Paper session Breast cancer Invited Discussant one LBA4 and 54O (PDF Format)Proffered Paper session Breast cancer Invited Discussant one LBA5 and 55O (Video MP4 Format)Proffered Paper session Breast cancer Invited Discussant one LBA5 and 55O (PDF Format)Proffered Paper session Breast cancer Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER+) breast cancer (Video MP4 Format)Proffered Paper session Breast cancer Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER+) breast cancer (PDF Format)Proffered Paper session Breast cancer Q&A and discussion 1 (Video MP4 Format)Proffered Paper session Breast cancer Q&A and discussion 2 (Video MP4 Format)Proffered Paper session Breast cancer Sacituzumab govitecan (SG) vs treatment of physician’s choice (Video MP4 Format)Proffered Paper session Breast cancer Sacituzumab govitecan (SG) vs treatment of physician’s choice (PDF Format)Proffered Paper session Gastrointestinal tumours Invited Discussant – surgical perspective of 129O and 130O (Video MP4 Format)Proffered Paper session Gastrointestinal tumours Invited Discussant – surgical perspective of 129O and 130O (PDF Format)Proffered Paper session Gastrointestinal tumours Invited Discussant 129O and 130O (Video MP4 Format)Proffered Paper session Gastrointestinal tumours Invited Discussant 129O and 130O (PDF Format)Proffered Paper session Gastrointestinal tumours Invited Discussant 89O (Video MP4 Format)Proffered Paper session Gastrointestinal tumours Invited Discussant 89O (PDF Format)Proffered Paper session Gastrointestinal tumours Long-term outcomes of intraoperative chemotherapy with 5-FU (Video MP4 Format)Proffered Paper session Gastrointestinal tumours Long-term outcomes of intraoperative chemotherapy with 5-FU (PDF Format)Proffered Paper session Gastrointestinal tumours Pathological complete response (pCR) to durvalumab plus 5-fluorouracil (Video MP4 Format)Proffered Paper session Gastrointestinal tumours Pathological complete response (pCR) to durvalumab plus 5-fluorouracil (PDF Format)Proffered Paper session Gastrointestinal tumours Q&A and discussion 1 (Video MP4 Format)Proffered Paper session Gastrointestinal tumours Q&A and discussion 2 (Video MP4 Format)Proffered Paper session Gastrointestinal tumours The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 (Video MP4 Format)Proffered Paper session Gastrointestinal tumours The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 (PDF Format)Proffered Paper session Genitourinary tumours Association of enzalutamide (ENZA) duration of treatment (Video MP4 Format)Proffered Paper session Genitourinary tumours Association of enzalutamide (ENZA) duration of treatment (PDF Format)Proffered Paper session Genitourinary tumours Darolutamide (DARO) in combination with androgen-deprivation therapy (Video MP4 Format)Proffered Paper session Genitourinary tumours Darolutamide (DARO) in combination with androgen-deprivation therapy (PDF Format)Proffered Paper session Genitourinary tumours Invited Discussant 255O, 256O and 257O (Video MP4 Format)Proffered Paper session Genitourinary tumours Invited Discussant 255O, 256O and 257O (PDF Format)Proffered Paper session Genitourinary tumours Prostate-specific antigen response to different real-world treatments (Video MP4 Format)Proffered Paper session Genitourinary tumours Prostate-specific antigen response to different real-world treatments (PDF Format)Proffered Paper session Genitourinary tumours Q&A and discussion (Video MP4 Format)Proffered Paper session Head and neck cancer A phase Ib II study of nanatinostat (Nstat) (Video MP4 Format)Proffered Paper session Head and neck cancer A phase Ib II study of nanatinostat (Nstat) (PDF Format)Proffered Paper session Head and neck cancer Artificial intelligence-powered spatial analysis of tumor microenvironment (Video MP4 Format)Proffered Paper session Head and neck cancer Artificial intelligence-powered spatial analysis of tumor microenvironment (PDF Format)Proffered Paper session Head and neck cancer Construction of an immune-related adverse events prediction model (Video MP4 Format)Proffered Paper session Head and neck cancer Construction of an immune-related adverse events prediction model (PDF Format)Proffered Paper session Head and neck cancer Efficacy and safety of ENZ-124 versus innovator cetuximab (Video MP4 Format)Proffered Paper session Head and neck cancer Efficacy and safety of ENZ-124 versus innovator cetuximab (PDF Format)Proffered Paper session Head and neck cancer Invited Discussant 353O and 354O (Video MP4 Format)Proffered Paper session Head and neck cancer Invited Discussant 353O and 354O (PDF Format)Proffered Paper session Head and neck cancer Invited Discussant 355O and 356O (Video MP4 Format)Proffered Paper session Head and neck cancer Invited Discussant 355O and 356O (PDF Format)Proffered Paper session Head and neck cancer Q&A and discussion 1 (Video MP4 Format)Proffered Paper session Head and neck cancer Q&A and discussion 2 (Video MP4 Format)Proffered Paper session Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy among A MARIPOSA-2 subgroup analysis (Video MP4 Format)Proffered Paper session Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy among A MARIPOSA-2 subgroup analysis (PDF Format)Proffered Paper session Thoracic cancer Amivantamab plus lazertinib vs osimertinib as first-line treatment among (Video MP4 Format)Proffered Paper session Thoracic cancer Amivantamab plus lazertinib vs osimertinib as first-line treatment among (PDF Format)Proffered Paper session Thoracic cancer Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor (Video MP4 Format)Proffered Paper session Thoracic cancer Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor (PDF Format)Proffered Paper session Thoracic cancer Invited Discussant LBA10 and LBA11 (Video MP4 Format)Proffered Paper session Thoracic cancer Invited Discussant LBA10 and LBA11 (PDF Format)Proffered Paper session Thoracic cancer Invited Discussant LBA12 (Video MP4 Format)Proffered Paper session Thoracic cancer Invited Discussant LBA12 (PDF Format)Proffered Paper session Thoracic cancer Q&A and discussion 1 (Video MP4 Format)Proffered Paper session Thoracic cancer Q&A and discussion 2 (Video MP4 Format)Radiation oncology session 1 Clinical case 1 (Video MP4 Format)Radiation oncology session 1 Clinical case 1 (PDF Format)Radiation oncology session 1 Clinical case 2 (PDF Format)Radiation oncology session 1 General discussion and conclusions (Video MP4 Format)Radiation oncology session 1 Real world consensus status on oligometastasis management- Korean caregivers perspective (Video MP4 Format)Radiation oncology session 1 Real world consensus status on oligometastasis management- Korean caregivers perspective (PDF Format)Radiation oncology session 1 Role of new generation TKIs vs SRS in metastatic NSCLC (Video MP4 Format)Radiation oncology session 1 Role of new generation TKIs vs SRS in metastatic NSCLC (PDF Format)Radiation oncology session 1 Single or fractionated radiosurgery for oligomets What have we learnt from SAFRON trial experience (Video MP4 Format)Radiation oncology session 1 Single or fractionated radiosurgery for oligomets What have we learnt from SAFRON trial experience (PDF Format)Radiation oncology session 2 Current status of SBRT in lung cancer (Video MP4 Format)Radiation oncology session 2 Current status of SBRT in lung cancer (PDF Format)Radiation oncology session 2 General discussion and conclusions (Video MP4 Format)Radiation oncology session 2 State of the art of radiotherapy in advanced prostate cancer (Video MP4 Format)Radiation oncology session 2 State of the art of radiotherapy in advanced prostate cancer (PDF Format)Seagen What’s next for ADCs in oncology Advances in integrin targeting (Video MP4 Format)Seagen What’s next for ADCs in oncology Multimodal immune targeting with ADCs (Video MP4 Format)Seagen What’s next for ADCs in oncology Panel discussion, live Q&A, and conclusions (Video MP4 Format)Seagen What’s next for ADCs in oncology State of the art and perspectives (Video MP4 Format)Seagen What’s next for ADCs in oncology Welcome and introduction (Video MP4 Format)Supporting shared decision making in face of uncertainty Advance care planning and serious illness conversations (Video MP4 Format)Supporting shared decision making in face of uncertainty Advance care planning and serious illness conversations (PDF Format)Supporting shared decision making in face of uncertainty Q&A and discussion (Video MP4 Format)Supporting shared decision making in face of uncertainty Supporting caregivers of patients with advanced cancer (Video MP4 Format)Supporting shared decision making in face of uncertainty Supporting caregivers of patients with advanced cancer (PDF Format)Transition from hormone-sensitive to castration-resistant prostate cancer Introduction to the session and presentation of case condition (Video MP4 Format)Transition from hormone-sensitive to castration-resistant prostate cancer Introduction to the session and presentation of case condition (PDF Format)Transition from hormone-sensitive to castration-resistant prostate cancer Pragmatic approach to treatment selection in metastatic castration-resistant prostate cancer (mCRPC) (Video MP4 Format)Transition from hormone-sensitive to castration-resistant prostate cancer Pragmatic approach to treatment selection in metastatic castration-resistant prostate cancer (mCRPC) (PDF Format)Transition from hormone-sensitive to castration-resistant prostate cancer Progression of the case (Video MP4 Format)Transition from hormone-sensitive to castration-resistant prostate cancer Progression of the case (PDF Format)Transition from hormone-sensitive to castration-resistant prostate cancer PSMA imaging and theranostics (Video MP4 Format)Transition from hormone-sensitive to castration-resistant prostate cancer PSMA imaging and theranostics (PDF Format)Transition from hormone-sensitive to castration-resistant prostate cancer Q&A and discussion (Video MP4 Format)Transition from hormone-sensitive to castration-resistant prostate cancer Use of PARP inhibitors in prostate cancer- Current data and future directions (Video MP4 Format)Transition from hormone-sensitive to castration-resistant prostate cancer Use of PARP inhibitors in prostate cancer- Current data and future directions (PDF Format)Treatment optimisation in early triple negative breast cancer (TNBC) Optimal application of preoperative immunotherapy and management of residual disease (Video MP4 Format)Treatment optimisation in early triple negative breast cancer (TNBC) Optimal application of preoperative immunotherapy and management of residual disease (PDF Format)Treatment optimisation in early triple negative breast cancer (TNBC) Q&A and discussion (Video MP4 Format)Treatment optimisation in early triple negative breast cancer (TNBC) What is the optimal systemic treatment of stage 1 TNBC (Video MP4 Format)Treatment optimisation in early triple negative breast cancer (TNBC) What is the optimal systemic treatment of stage 1 TNBC (PDF Format)What’s new in 2023 (Investigational immunotherapy) Genetically-engineered cellular therapies- Expanding indications (Video MP4 Format)What’s new in 2023 (Investigational immunotherapy) Genetically-engineered cellular therapies- Expanding indications (PDF Format)What’s new in 2023 (Investigational immunotherapy) Q&A and discussion (Video MP4 Format)What’s new in 2023 (Investigational immunotherapy) Vaccines for cancer treatment- Finally primetime (Video MP4 Format)What’s new in 2023 (Investigational immunotherapy) Vaccines for cancer treatment- Finally primetime (PDF Format)What’s new in 2023 (Investigational immunotherapy) Why adjuvant when there is neoadjuvant (Video MP4 Format)What’s new in 2023 (Investigational immunotherapy) Why adjuvant when there is neoadjuvant (PDF Format)Young Oncologists clinical cases discussion A Rare Case of Breast Cancer in A Postpartum Female with Reoccurrence of Breast Cancer During Pregnancy (Video MP4 Format)Young Oncologists clinical cases discussion A Rare Case of Breast Cancer in A Postpartum Female with Reoccurrence of Breast Cancer During Pregnancy (PDF Format)Young Oncologists clinical cases discussion Chemotherapy-resistant epithelioid trophoblastic tumor successfully treated by immunotherapy (Video MP4 Format)Young Oncologists clinical cases discussion Chemotherapy-resistant epithelioid trophoblastic tumor successfully treated by immunotherapy (PDF Format)Young Oncologists clinical cases discussion In-depth analysis of unknown NTRK1-fusion gene detected in DNA-based (Video MP4 Format)Young Oncologists clinical cases discussion In-depth analysis of unknown NTRK1-fusion gene detected in DNA-based (PDF Format)Young Oncologists clinical cases discussion Invited Discussant YO16 and YO20 (Video MP4 Format)Young Oncologists clinical cases discussion Invited Discussant YO16 and YO20 (PDF Format)Young Oncologists clinical cases discussion Invited Discussant YO2 and YO31 (Video MP4 Format)Young Oncologists clinical cases discussion Invited Discussant YO2 and YO31 (PDF Format)Young Oncologists clinical cases discussion Invited Discussant YO5 and YO26 (Video MP4 Format)Young Oncologists clinical cases discussion Invited Discussant YO5 and YO26 (PDF Format)Young Oncologists clinical cases discussion Q&A and discussion 1 (Video MP4 Format)Young Oncologists clinical cases discussion Q&A and discussion 2 (Video MP4 Format)Young Oncologists clinical cases discussion Q&A and discussion 3 (Video MP4 Format)Young Oncologists clinical cases discussion Solitary Cardiac Metastasis in BRAFV600E Mutation Colon Cancer (Video MP4 Format)Young Oncologists clinical cases discussion Solitary Cardiac Metastasis in BRAFV600E Mutation Colon Cancer (PDF Format)Young Oncologists clinical cases discussion The efficacy and safety of aumolertinib plus alectinib in NSCLC patients haboring EGFR 19 Del (Video MP4 Format)Young Oncologists clinical cases discussion The efficacy and safety of aumolertinib plus alectinib in NSCLC patients haboring EGFR 19 Del (PDF Format)Young Oncologists clinical cases discussion Their voices are louder than yours, doctor Unspoken challenges managing breast cancer (Video MP4 Format)Young Oncologists clinical cases discussion Their voices are louder than yours, doctor Unspoken challenges managing breast cancer (PDF Format)